A Chinese medicine composition and its pharmaceutical use

Through the preparation of traditional Chinese medicine compositions with components such as Haifeng Teng, the problem of insufficient effectiveness of existing traditional Chinese medicine in treating angina pectoris was solved, and the effect of significantly improving myocardial blood supply and reducing angina pectoris attacks was achieved. The total clinical effective efficiency reached 88%.

CN117018144BInactive Publication Date: 2024-11-26SHANDONG UNIV QILU HOSPITAL DEZHOU HOSPITAL (DEZHOU PEOPLES HOSPITAL)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311173713.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-12
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Although the existing traditional Chinese medicine treatment methods for angina pectoris have certain effects, there are still shortcomings in improving myocardial blood supply and preventing symptoms, especially the treatment effect of angina pectoris caused by coronary heart disease is not significant enough.

Method used

A Chinese medicine composition is adopted, containing components such as sauerkum, Bupleurum, Tulip, Leech, Centipede, Red Peony, Asarum, Asparagus, Ginseng, Betel nut, Atractylodes, Angelica sinensis, Citrus aurantium and other components, and is cooked, concentrated and prepared by decoction. Prepare oral solid or liquid preparations by pellets and other processes, which are used to improve myocardial blood supply and relieve symptoms such as chest tightness and chest pain.

Benefits of technology

This traditional Chinese medicine composition significantly improves the NO level in serum, protects and repairs cardiomyocytes, and has a total clinical effective efficiency of 88%, effectively reducing the number of angina attacks and onset time, and significantly improving the patient's symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117018144B_ABST
    Figure CN117018144B_ABST
Patent Text Reader

Abstract

The present invention discloses a Chinese medicine composition and its medical use, belonging to the technical field of Chinese medicine. The Chinese medicine composition of the present invention contains the following components by weight: 30-90 parts of bupleurum, 40-120 parts of curcuma, 5-15 parts of leech, 3-11 parts of centipede, 11-25 parts of red peony root, 3-6 parts of asarum, 20-40 parts of astragalus, 11-24 parts of ginseng, 5-19 parts of betel nut, 7-29 parts of atractylodes, 10-30 parts of angelica, 8-19 parts of immature bitter orange, and 10-20 parts of kadzu vine. The present invention can effectively relieve clinical symptoms such as chest tightness and chest pain, and effectively treat angina pectoris of coronary heart disease, with a clinical treatment effective rate of 88%, and a remarkable effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition and application thereof in preparing a medicine for treating angina pectoris. Background Art

[0002] Angina pectoris is a group of symptoms and a clinical syndrome of myocardial ischemia caused by a temporary imbalance between myocardial hypoxia and oxygen supply. Myocardial ischemia can be caused by an increase in myocardial oxygen demand that exceeds the blood supply capacity of the diseased coronary arteries, or by a decrease in coronary artery blood supply, or both. It is characterized by paroxysmal squeezing pain in the front chest, which may be accompanied by other symptoms. The pain is mainly located behind the sternum and can radiate to the precordial area and left upper limb. It often occurs during labor or emotional excitement. Each attack lasts 3 to 5 minutes and may occur once every few days or several times a day.

[0003] Traditional Chinese medicine has certain advantages in the treatment of angina pectoris. After long-term chronic conditioning with traditional Chinese medicine, it can prevent the occurrence of complications, reduce the number of angina attacks, improve myocardial blood supply, and improve microcirculation. The preventive effect is better than the therapeutic effect. The main blood-activating and stasis-removing drugs currently used include extracts of salvia miltiorrhiza, safflower, ginkgo biloba, Panax notoginseng, etc., or single-ingredient drugs or compound oral administration, which can improve myocardial blood supply to a certain extent, and long-term use has certain effects. Summary of the invention

[0004] The main purpose of the present invention is to provide a traditional Chinese medicine composition, which has a good clinical effect on treating angina pectoris.

[0005] The present invention adopts the following technical solutions to achieve the above purpose:

[0006] A Chinese medicine composition, comprising the following components in parts by weight:

[0007]

[0008] 10-20 servings of Pieris paniculata.

[0009] Further, the following components are contained in parts by weight:

[0010]

[0011]

[0012] The present invention also provides the use of the above-mentioned Chinese medicine composition in preparing a drug for treating angina pectoris. The angina pectoris can be angina pectoris caused by coronary heart disease, or can be caused by heart diseases such as aortic valve stenosis and cardiomyopathy.

[0013] The Chinese medicine composition of the present invention can also be used to prepare medicines for improving chest pain, chest tightness, shortness of breath, palpitations and fatigue.

[0014] The present invention also provides a Chinese medicine preparation prepared from the Chinese medicine composition, wherein the Chinese medicine preparation is an oral preparation.

[0015] Furthermore, the oral preparation is an oral solid preparation and / or an oral liquid preparation.

[0016] Furthermore, the oral solid preparation is a tablet, a capsule, a granule and / or a pill; the oral liquid preparation is a decoction, an oral liquid and / or a syrup.

[0017] The present invention has the following beneficial effects:

[0018] 1. In the present invention, Curcuma can promote blood circulation and qi circulation, relieve pain, Bupleurum can raise yang, soothe the liver and relieve depression, and are the monarch medicine in the prescription; Leech and centipede have the effect of breaking blood and removing blood stasis, Red Peony Root clears heat and cools blood, promotes blood circulation and removes blood stasis, Asarum can dispel wind and relieve pain, and are the minister medicine in the prescription; Astragalus invigorates qi and raises yang, relieves stagnation and relieves numbness, Ginseng greatly replenishes vital energy, promotes fluid and nourishes blood, Areca promotes qi and diuresis, Atractylodes macrocephala strengthens the spleen and replenishes qi, Angelica sinensis invigorates blood and promotes blood circulation, and relieves pain; Citrus aurantium dispels lumps; is the adjuvant in the prescription; Piper mesenteriae dredges the meridians and stops pain, and is the messenger in the prescription. The cooperation of all the medicines plays the effects of promoting blood circulation and qi circulation and removing blood stasis, and has a good therapeutic effect on chest tightness and chest pain.

[0019] 2. Pharmacodynamic experiments have confirmed that the composition of the present invention can regulate the NO level in serum and has a good protective and repairing effect on myocardial cells.

[0020] 3. Clinical trials have confirmed that the Chinese medicine composition of the present invention has a good effect in the clinical treatment of angina pectoris caused by coronary heart disease, with a total effective rate of up to 88%. It can effectively relieve patients' clinical symptoms such as chest tightness, chest pain, palpitations, and reduce the number and duration of angina attacks, with significant effects.

[0021] Agent: Sea Breeze Vine. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 : NO levels in serum of rats in each group in pharmacodynamic experiments

[0023] Figure 2 : The myocardial cell structure of rats in each group in the pharmacodynamic experiment, where A is the blank group, B is the model group, C is the experimental group 1, D is the experimental group 2, and E is the experimental group 3. Specific embodiments

[0024] The present invention is further explained below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. After reading the present invention, various equivalent modifications to the present invention by those skilled in the art all fall within the scope of protection of the claims of this application.

[0025] Example 1

[0026] Take 55g of Bupleurum, 70g of Curcuma, 10g of Leech, 7g of Scolopendra, 18g of Red Peony Root, 5g of Asarum, 28g of Astragalus, 16g of Ginseng, 13g of Areca, 18g of Atractylodes, 17g of Angelica, 12g of Citrus aurantium, and 15g of Piper mesenteriae, add water and boil to obtain a decoction.

[0027] Example 2

[0028] Take 60g of Bupleurum, 60g of Curcuma, 12g of Leech, 5g of Scolopendra, 20g of Red Peony Root, 3g of Asarum, 30g of Astragalus, 15g of Ginseng, 15g of Areca, 15g of Atractylodes, 20g of Angelica, 10g of Citrus aurantium, and 20g of Piper mesenteriae, add water and boil, filter the decoction, concentrate under reduced pressure into a thick paste, add starch and sucrose, wet granulate, and dry to obtain granules.

[0029] Example 3

[0030] Take 30g of bupleurum, 120g of curcuma, 5g of leech, 11g of centipede, 11g of red peony root, 6g of asarum, 20g of astragalus, 24g of ginseng, 5g of areca catechu, 29g of atractylodes, 10g of angelica, 19g of immature bitter orange, and 10g of kadzu vine, add water and boil, filter the decoction, add sodium benzoate, and fill it to obtain the oral solution.

[0031] Example 4

[0032] Take 50g of Bupleurum, 80g of Curcuma, 8g of Leech, 8g of Scolopendra, 15g of Red Peony Root, 6g of Asarum, 25g of Astragalus, 20g of Ginseng, 10g of Areca, 20g of Atractylodes, 15g of Angelica, 15g of Citrus Aurantium, and 10g of Piper mesenteriae, add water and boil, filter the decoction, concentrate under reduced pressure to a thick paste, add dextrin, starch, and magnesium stearate, granulate, and press into tablets to obtain tablets.

[0033] Example 5

[0034] Take 90g of Bupleurum, 40g of Curcuma, 15g of Leech, 3g of Scolopendra, 25g of Red Peony Root, 3g of Asarum, 40g of Astragalus, 11g of Ginseng, 19g of Areca, 7g of Atractylodes, 30g of Angelica, 8g of Citrus Aurantium, and 20g of Piper mesenteriae, add water and boil, filter the decoction, concentrate under reduced pressure to a thick paste, add dextrin, wet granulate, dry, and put into capsules to obtain capsules.

[0035] Pharmacodynamics experiments

[0036] In order to verify the therapeutic effect of the Chinese medicine composition of the present invention, the inventors conducted relevant pharmacodynamics experiments. The inventors would like to explain that the following experimental studies were conducted on the basis of the acute toxicity test and the long-term toxicity test to prove the safety of the drug, the dosage in the experimental studies was within the safe dosage range, and the following animal models were conducted on the basis of reference to existing literature.

[0037] The therapeutic effect of the Chinese medicine composition of the present invention on rats with angina pectoris caused by coronary heart disease

[0038] 1. Materials and Methods

[0039] 1.1 Experimental animals

[0040] SD rats, weighing 200 ± 20 g, were purchased from Jiangsu Aikem Testing Co., Ltd., license number: SYXK (Su) 2019-0035. They were adaptively raised for one week before the experiment.

[0041] 1.2 Experimental drugs

[0042] According to the composition ingredients in Examples 1-3, various medicinal materials were taken, decocted with water, and concentrated to 50 mL, which were used as medicines for Experimental Group 1, Experimental Group 2, and Experimental Group 3, respectively.

[0043] 1.3 Dosage

[0044] 5ml / kg

[0045] 1.4 Experimental process

[0046] Modeling process: The rats were anesthetized, lying supine on the test bench, connected to a recorder, and the rat electrocardiogram was recorded. The rats were dissected and the femoral vein was isolated, and intravenous catheterization was performed. After completion, 6U / kg of posterior pituitary hormone (concentration of 2U / mL) was injected.

[0047] Grouping: The rats with successful modeling were randomly divided into model group, experimental group 1, experimental group 2, and experimental group 3, with 10 rats in each group; another 10 rats were taken as the blank group, which underwent sham surgery and injected with an equal amount of normal saline.

[0048] Drug administration: Experimental groups 1-3 were given corresponding drugs, and the blank group and model group were given an equal amount of normal saline for 20 days.

[0049] 2. Project indicator testing

[0050] 2.1 NO expression level in serum

[0051] Blood was collected from the abdominal aorta, serum was separated, and NO in serum was detected by nitrate reductase method.

[0052] 2.2 Pathological changes of myocardial cells

[0053] After blood was collected from rats, myocardial tissue was isolated and sliced, and the morphological changes of the tissue were observed under a light microscope.

[0054] 3. Results and Analysis

[0055] 3.1 Compared with the blank group, the NO levels in the serum of rats in other groups were increased, but after treatment, the NO levels in the serum of rats in each drug-treated group were decreased compared with the model group. Figure 1 .

[0056] 3.2 In the blank group, the myocardial fibers of myocardial tissue were arranged neatly, the mitochondria were regular in shape and intact in membrane; the nuclear membrane was intact and the chromatin was evenly distributed; in the model group, the myocardial fibers of myocardial tissue were arranged disorderly, the mitochondrial membrane was partially ruptured, the lysosomes increased, and the nuclear chromatin was marginalized. Compared with the model group, the myocardial fibers of each drug-treated group were arranged neatly; the mitochondrial membrane was relatively intact; and the nuclear membrane chromatin was evenly distributed. Figure 2 .

[0057] Clinical effect verification

[0058] 1 Materials and methods

[0059] 1.1 General Information

[0060] Fifty patients with angina pectoris due to coronary heart disease admitted to our hospital were randomly divided into a control group (25 cases) and an observation group (25 cases). The age of the patients in the control group ranged from 55 to 73 years old, with an average age of (65.4±3.8) years old; the course of disease was 1.8 to 6.2 years. The age of the patients in the observation group ranged from 53 to 78 years old, with an average age of (66.7±4.3) years old; the course of disease was 1.5 to 6.5 years. There was no significant difference in the basic data of the two groups of patients, P>0.05.

[0061] 1.2 Diagnostic criteria

[0062] It meets the diagnostic criteria for angina pectoris due to coronary heart disease in the "Guidelines for the Diagnosis and Treatment of Chronic Stable Angina Pectoris" and the syndrome differentiation criteria for chest pain due to qi deficiency and blood stasis in the "Guidelines for Clinical Research of New Chinese Medicines (Trial)". Main symptoms: chest pain and chest tightness; secondary symptoms: shortness of breath, palpitations, dry mouth and loss of appetite, pale purple tongue, weak or astringent pulse.

[0063] 1.3 Methods

[0064] 1.3.1 Treatment methods

[0065] The control group implemented conventional western medicine treatment, taking ticagrelor tablets orally, before or after meals, 90 mg / time, twice / day.

[0066] The observation group was given the decoction obtained in Example 1 on the basis of the above treatment, twice a day, 500 ml / dose, taken in the morning and evening.

[0067] Both groups were treated continuously for 1 month.

[0068] 1.3.2 Observation indicators

[0069] It includes TCM symptom score, angina attack time and frequency, and compares their comprehensive therapeutic effects.

[0070] TCM symptom scores: before and after treatment, the symptoms of chest tightness, chest pain, palpitations, shortness of breath, and dry mouth were scored as 0, 1, 2, and 3 points respectively, with a total score of 0-15 points. The higher the score, the more severe the symptom.

[0071] The frequency and duration of angina pectoris attacks were compared between the two groups before and after treatment.

[0072] The comprehensive efficacy can be divided into marked effect (symptoms basically disappeared, or the TCM symptom score decreased by more than 70%, and the electrocardiogram was basically normal), effective (the TCM symptom score decreased by 40-70%, and the electrocardiogram showed some improvement), and ineffective (did not meet the above standards). Total effective rate = marked effective rate + effective rate.

[0073] 1.3.3 Statistical methods

[0074] SPSS 22.0 software was used for data processing and quantitative data The t test was used, and P < 0.05 indicated that the data difference was statistically significant.

[0075] 2 Results

[0076] 2.1 Comparison of TCM symptom scores

[0077] Before treatment, there was no significant difference in the TCM symptom scores between the two groups (P>0.05), but after treatment, the TCM symptom scores of the observation group were significantly lower than those of the control group (P<0.05). See Table 1.

[0078] Table 1 Comparison of TCM syndrome scores before and after treatment in 2 groups of patients ( point)

[0079]

[0080] Note: Compared with before treatment, # P<0.05

[0081] 2.2 Comparison of duration and frequency of angina attacks

[0082] Before treatment, there was no significant difference in the duration and frequency of angina pectoris between the two groups (P>0.05); after treatment, the duration of angina pectoris in the observation group was shorter than that in the control group, and the frequency of angina pectoris was less than that in the control group. See Table 2.

[0083] Table 2 Comparison of angina attack time and frequency in 2 groups of patients before and after treatment

[0084]

[0085] Note: Compared with before treatment, # P<0.05

[0086] 2.3 Comparison of comprehensive clinical efficacy

[0087] After treatment, 5 cases in the control group showed marked effect, 15 cases showed effective effect, 5 cases showed ineffective effect, and the total effective rate was 80%; 8 cases in the treatment group showed marked effect, 14 cases showed effective effect, 3 cases showed ineffective effect, and the total effective rate was 88%. The total effective rate of the treatment group was significantly higher than that of the control group. See Table 3.

[0088] Table 3 Comparison of clinical efficacy between groups 2

[0089] Group Number of cases Significantly effective (example) Valid (Example) Invalid (Example) Total effective rate (%) Control group 25 5 15 5 80.00 Observation Group 25 8 14 3 88.00

Claims

1. Use of a Chinese medicine composition in preparing a drug for treating angina pectoris, characterized in that: The Chinese medicine composition is composed of the following Chinese medicine ingredients in parts by weight: 30-90 parts of Bupleurum Root, 40-120 parts of Curcuma Radix, 5-15 parts of Leech 3-11 parts of centipede 11-25 parts of red peony root 3-6 parts of asarum 20-40 parts of Astragalus 11-24 parts of Ginseng 5-19 parts of Areca 7-29 parts of Atractylodes macrocephala, 10-30 parts of Angelica sinensis, 8-19 parts of Citrus aurantium 10-20 servings of Pieris paniculata.

2. The use according to claim 1, characterized in that In parts by weight, it is composed of the following ingredients: 50-60 parts of Radix Bupleuri, 60-80 parts of Radix Curcumae, 8-12 parts of Leech 5-8 parts of centipede 15-20 parts of red peony root 3-6 parts of asarum 25-30 parts of Astragalus 15-20 parts of Ginseng 10-15 parts of Areca 15-20 parts of Atractylodes macrocephala, 15-20 parts of Angelica sinensis, 10-15 parts of Citrus aurantium 10-20 servings of Pieris paniculata.

3. The use according to claim 1, characterized in that The angina pectoris is angina pectoris caused by coronary heart disease.

4. Use of a Chinese medicine composition in the preparation of a drug for improving chest pain in angina pectoris, characterized in that: The Chinese medicine composition is the Chinese medicine composition according to claim 1 or 2.

5. A Chinese medicine preparation, characterized in that: The Chinese medicine preparation is prepared from the Chinese medicine composition according to claim 1 or 2.

6. The Chinese medicine preparation according to claim 5, characterized in that: The traditional Chinese medicine preparation is an oral preparation.

7. The Chinese medicine preparation according to claim 6, characterized in that: The oral preparations are oral solid preparations and oral liquid preparations.

8. The Chinese medicine preparation according to claim 7, characterized in that: The oral solid preparations are tablets, capsules, granules and pills.

9. The Chinese medicine preparation according to claim 7, characterized in that: The oral liquid preparation is a decoction, an oral liquid, or a syrup.